Waters
Waters Q2 Revenues up 31 Percent
The company posted revenues of $681.6 million, up 31 percent from $520.0 million in Q2 2020, and above the average Wall Street estimate of $621.5 million.
Evercore ISI Upgrades Waters to Outperform Based on Improved Fundamentals
The analysts cited opportunity in drug QC provided by Biogen's aducanumab approval as well as a new focus on markets like CROs and CDMOs.
The companies said that they envisioned the test, which is currently RUO, as potentially part of a mass spectrometry-based respiratory virus panel.
Vendors including Bruker, Sciex, and Waters this month launched instruments featuring new technologies boosting sensitivity and resolution.
May 5, 2021
Waters Posts 31 Percent Increase in Q1 Revenues
Oct 27, 2020
Waters Q3 Revenues Up 3 Percent
Jun 12, 2020
Apr 28, 2020
Waters Q1 Revenues Down 10 Percent
Jan 15, 2020
Jan 2, 2020
Oct 29, 2019
Waters Q3 Revenues Flat, Fall Short of Expectations
Oct 9, 2019
Waters Stock Downgraded by Barclays
Aug 29, 2019